News briefing: Locus Biosciences bags up to $12.1M for CRISPR antibacterial; Old Vertex drug heads to PhIII for dementia
In its latest effort to spur the development of new antibacterial drugs, the non-profit CARB-X is awarding Locus Biosciences up to $12.1 million for its CRISPR Cas-3-enhanced bacteriophage for serious recurring urinary tract infections (rUTIs).
The Morrisville, NC-based biotech will receive up to $2.05 million initially, followed by up to $10 million more if it meets certain milestones. Its candidate, LBP-KP01, targets Klebsiella pneumoniae, a common cause of antibiotic-resistant infections like rUTIs. The CARB-X funds will support preclinical development, potentially leading up to Phase I.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.